Literature DB >> 23458927

Transplantation: The promise of co-stimulatory blockade in transplantation.

Rolf N Barth1, Jonathan S Bromberg.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23458927     DOI： 10.1038/nrneph.2013.37

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

Authors:  Christian P Larsen; Thomas C Pearson; Andrew B Adams; Paul Tso; Nozomu Shirasugi; Elizabeth Strobert; Dan Anderson; Shannon Cowan; Karen Price; Joseph Naemura; John Emswiler; JoAnne Greene; Lori Ann Turk; Jurgen Bajorath; Robert Townsend; David Hagerty; Peter S Linsley; Robert J Peach
Journal:  Am J Transplant       Date:  2005-03       Impact factor: 8.086

Review 2.  Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells.

Authors:  Hélène Bour-Jordan; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 3.  Deciphering antibody-mediated rejection: new insights into mechanisms and treatment.

Authors:  Mark D Stegall; James M Gloor
Journal:  Curr Opin Organ Transplant       Date:  2010-02       Impact factor: 2.640

4.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.

Authors:  C P Larsen; E T Elwood; D Z Alexander; S C Ritchie; R Hendrix; C Tucker-Burden; H R Cho; A Aruffo; D Hollenbaugh; P S Linsley; K J Winn; T C Pearson
Journal:  Nature       Date:  1996-05-30       Impact factor: 49.962

5.  The risk and opportunity of homeostatic repopulation.

Authors:  P Stock; A D Kirk
Journal:  Am J Transplant       Date:  2011-05-12       Impact factor: 8.086

6.  CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.

Authors:  A D Kirk; D M Harlan; N N Armstrong; T A Davis; Y Dong; G S Gray; X Hong; D Thomas; J H Fechner; S J Knechtle
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

7.  Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy.

Authors:  M C Lowe; I R Badell; A P Turner; P W Thompson; F V Leopardi; E A Strobert; C P Larsen; A D Kirk
Journal:  Am J Transplant       Date:  2012-12-27       Impact factor: 8.086

8.  Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

Authors:  F Vincenti; C P Larsen; J Alberu; B Bresnahan; V D Garcia; J Kothari; P Lang; E Mancilla Urrea; P Massari; G Mondragon-Ramirez; R Reyes-Acevedo; K Rice; L Rostaing; S Steinberg; J Xing; M Agarwal; M B Harler; B Charpentier
Journal:  Am J Transplant       Date:  2011-10-12       Impact factor: 8.086

9.  Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion.

Authors:  D J Lo; D J Anderson; T A Weaver; F Leopardi; M Song; A B Farris; E A Strobert; J Jenkins; N A Turgeon; A K Mehta; C P Larsen; A D Kirk
Journal:  Am J Transplant       Date:  2013-01-11       Impact factor: 8.086
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.